Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 851–900 of 75328
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
On July 31, 2026 (the “Effective Date”), Nicola Rossi, Chief Accounting Officer of Wyndham Hotels & Resorts, Inc. (the “Company”), will depart from the Company.
On May 14, 2026, Scott S. Prince, a director on the Board of Directors (the “Board”) of Apollo Commercial Real Estate Finance, Inc. (the “Company”), informed the Company that he will not be standing for re-election to the Board at the Company’s next annual meeting of stockholders.
On April 27, 2026, Planet 13 Holdings Inc. (the "Company") entered into a separation agreement with the Company’s former Chief Administrative Officer, Lee Fraser (the "Separation Agreement").
On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.
On May 12, 2026, Scott Ciccone notified the Company of his resignation as Chief Accounting Officer of the Company effective as of May 15, 2026. Mr. Ciccone’s resignation was not due to any disagreement with the Company
On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
Accordingly, Mr. Kanter’s Employment Agreement will expire and his employment with the Company will terminate on August 11, 2026.
On May 14, 2026, Local Bounti Corporation (the “Company”) notified Dane Almassy, the Company’s Chief Commercial Officer, that his employment with the Company ended effective May 14, 2026 (the “Separation Date”).
Effective May 8, 2026, Randall Keys ceased to serve as a member of the Board of Directors (the “Board”) of U.S. Energy Corp. (the “Company”) upon the expiration of his term
On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
the following named executive officers of Marine Products voluntarily resigned from any and all of their respective director, manager, or officer positions with Marine Products or any of its subsidiaries: Richard A. Hubbell, Ben M. Palmer and Michael L. Schmit.
Richard A. Hubbell, Jerry W. Nix, Susan R. Bell, Patrick J. Gunning, Gary Kolstad, Amy R. Kreisler, Stephen E. Lewis, Ben M. Palmer, Timothy C. Rollins and John F. Wilson.
On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.
On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
On May 11, 2026, Michael Woods resigned as a director of Roman DBDR Acquisition Corp. II (the “Company”), effective immediately.
On May 14, 2026, Dr. Donald G. Basile resigned as the Chief Technology Officer of the Company, effective immediately.
Mr. Bryan succeeds Nancy Buese, who by mutual agreement, stepped down from her role as Chief Financial Officer of the Company on May 11, 2026, effective as of the same date.
Tara Comonte, the Company’s former President and Chief Executive Officer, resigned from her position as President and Chief Executive Officer of the Company, effective March 31, 2026.
Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.
On May 15, 2026, Matthew Cohen resigned from his position as Chief Executive Officer and a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
On May 15, 2026, Katharyn Field resigned her position as a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
On May 15, 2026, Matthew Cohen resigned from his position as Chief Executive Officer and a member of our Board of Directors, which resignation was not in connection with any disagreement regarding our operations, policies or procedures.
Thomas E. Wiseman, who, as previously announced, retired as chairman effective as of OVBC’s 2026 annual meeting of shareholders
the vacancy created by the previously announced retirement of David W. Thomas as of the 2026 Annual Meeting.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
At the Effective Time, Barbara Jacobsmeyer, Jeffrey W. Bolton, Tina L. Brown-Stevenson, Charles M. Elson, Erin P. Hoeflinger, Stuart M. McGuigan, Mark W. Ohlendorf, Stephan S. Rodgers, Gregory S. Rush and Barry Schochet each resigned from the board of directors of the Company and from any and all committees thereof on which they served and ceased to be directors of the Company.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.